<DOC>
	<DOCNO>NCT02524236</DOCNO>
	<brief_summary>The primary objective study compare efficacy safety single injection 50 U 100 U dose BoNT-A treatment BPH-associated LUTS .</brief_summary>
	<brief_title>Effect 50 100 IU Doses Botox A Toxin Injection BPH Patients .</brief_title>
	<detailed_description>Patients method : Men symptomatic BPH invite participate prospective study . Inclusion criterion age 50 year , persistent moderate severe LUTS determine International Prostatic Symptom Score ( IPSS ) &gt; 8 , peak urinary flow rate le 12 mL/s , enlarge prostate gland digital rectal examination . Exclusion criterion history previous surgery BPH , presence urethral stenosis , urinary tract infection , prostate bladder cancer , history pelvic surgery radiotherapy , neurological disease , urinary retention BPH-associated complication require surgical treatment include bladder stone , bilateral hydronephrosis . Subjects undergo evaluation treatment , include urine analysis , serum creatinine , prostate-specific antigen ( PSA ) , Trans rectal prostatic Trans abdominal urinary tract sonography , uroflowmetry , measurement post-void residual volume ( PVR ) via abdominal ultrasonography . Just injection procedure , patient randomize receive either 50 U 100 U BoNT-A . - Intervention All patient submit intervention receive oral antibiotic ( oral levofloxacin flagyl 500 mg ) 2 day injection . Patients instructed avoid take anticoagulant , aspirin , least seven day prior procedure . An enema do two four hour ultrasound clean bowel . Injection procedure : With patient lie lateral position , local anesthesia perform 20 mL lidocaine 2 % solution inject transrectally via transrectal ultrasound wait 10-minutes . The two different BoNT-A dos ( 50 U 100 U ) reconstitute saline 0.9 % total volume 5 ml . All patient receive five injection 1 mL BoNT-A solution , include two injection lateral lobe ( one proximal one distal ) one injection median lobe . The injection depth 7-10 mm . After procedure , patient remain observation able void spontaneously without hematuria . Oral levofloxacin ( 500 mg day ) administer five day . Follow : Evaluation perform one week , 3 6 month treatment . They include clinical assessment LUTS IPSS score well measurement peak urinary flow rate post void residual volume . Serum PSA level prostate volume assess 6th month . The primary endpoint improvement IPSS score ( least 30 % improvement baseline 3 month IPSS and/or maximum urinary flow rate ) safety . The study stop 1 ) life threaten , disable fatal event relate BONT-A injection occur , 2 ) 40 % participant report moderate severe side effect relate botulinum toxin injection . After 3 month , patient show improvement within 50 u group reinjected another dose 100 u reevaluate 3 month reinjection . Statistical Analysis : Data express mean standard deviation ( SD ) range absolute value fraction . Intergroup change baseline continuous variable analyze analysis variance repeat measurement . Intragroup comparison perform use Student 's paired t-test . Fisher 's test use categorical variable . A sample size 17 group 80 % power detect difference mean 3.00 ( unit IPSS score ) , two-tailed significance level 0.05 le .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>persistent moderate severe LUTS determine International Prostatic Symptom Score ( IPSS ) &gt; 8 . peak urinary flow rate le 12 mL/s . enlarge prostate gland digital rectal examination . history previous surgery BPH . presence urethral stenosis . urinary tract infection . prostate bladder cancer . history pelvic surgery radiotherapy . neurological disease . urinary retention . BPHassociated complication require surgical treatment include bladder stone , bilateral hydronephrosis .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>BPH , OAB , Botox , dose response</keyword>
</DOC>